Drugs /

ny-eso-1 reactive tcr retroviral vector transduced autologous pbl

Back to Drugs List

Overview

NCI Definition [1]:
Human autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the NY-ESO-1 reactive TCR-transduced autologous PBLs bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL) killing of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types; the TCR is specific for NY-ESO-1:157-165.

Clinical Trials

View Clinical Trials for ny-eso-1 reactive tcr retroviral vector transduced autologous pbl

Ny-eso-1 reactive tcr retroviral vector transduced autologous pbl has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating ny-eso-1 reactive tcr retroviral vector transduced autologous pbl, 2 are phase 2 (1 open).

CTAG1A Expression, CTAG1B Expression, and HLA-A*02:01 Positive are the most frequent biomarker inclusion criteria for ny-eso-1 reactive tcr retroviral vector transduced autologous pbl clinical trials.

Cancer, malignant solid tumor, and meningioma are the most common diseases being investigated in ny-eso-1 reactive tcr retroviral vector transduced autologous pbl clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ny-Eso-1 Reactive Tcr Retroviral Vector Transduced Autologous Pbl
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ny-Eso-1 Reactive Tcr Retroviral Vector Transduced Autologous Pbl
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ny-eso-1 reactive tcr retroviral vector transduced autologous pbl and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-ny-eso-1 tcr gene-engineered lymphocytes, anti-ny-eso-1 tcr retroviral vector-transduced lymphocytes, anti-ny eso-1 mtcr pbl, anti-ny-eso-1 tcr retroviral vector transduced autologous pbl
Drug Target(s) [2]:
CTAG1B
NCIT ID [1]:
C90559

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.